Pharmacokinetics
-
Subject Areas on Research
- A finite element model for predicting the distribution of drugs delivered intracranially to the brain.
- A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor.
- A single-nucleotide polymorphism tagging set for human drug metabolism and transport.
- Applying pharmacokinetic principles to the management of drug poisoning.
- Assessing bioequivalence using genomic data.
- Assessing departure from dose linearity under a repeated measures incomplete block design.
- Clinical Pharmacology Studies in Critically Ill Children.
- Comments on the FDA draft guidance on biosimilar products.
- Coronary drug-eluting stent development: issues in trial design.
- Correcting for measurement error in individual-level covariates in nonlinear mixed effects models.
- Designing drug trials: considerations for pregnant women.
- Drug Dosing and Pharmacokinetics in Children With Obesity: A Systematic Review.
- Drug-drug interactions in older adults: which ones matter?
- Estimation and inference in pharmacokinetic models: the effectiveness of model reformulation and resampling methods for functions of parameters.
- Examining outlying subjects and outlying records in bioequivalence trials.
- First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.
- Gaps in Drug Dosing for Obese Children: A Systematic Review of Commonly Prescribed Emergency Care Medications.
- Harmonization of regulatory approaches for evaluating therapeutic equivalence and interchangeability of multisource drug products: workshop summary report.
- In vitro bioequivalence testing.
- Journal club: gastric emptying in the poisoned patient.
- Kinetic aspects of drug disposition in the lungs.
- Lessons learned in pediatric clinical research to evaluate safe and effective use of drugs in pregnancy.
- Mean difference vs. variability reduction: tradeoffs in aggregate measures for individual bioequivalence. FDA Individual Bioequivalence Working Group.
- Microdosing and drug development: past, present and future.
- Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies.
- On assessing bioequivalence using genomic data with model misspecification.
- On the assessment of dose proportionality: a comparison of two slope approaches.
- Outlier detection in bioavailability/bioequivalence studies.
- Pharmacogenetics goes genomic.
- Pharmacokinetic studies in infants using minimal-risk study designs.
- Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%).
- Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology.
- Probabilistic pharmacokinetic models of decompression sickness in humans: Part 2, coupled perfusion-diffusion models.
- Sample size determination for the two one-sided tests procedure in bioequivalence.
- Smooth nonparametric maximum likelihood estimation for population pharmacokinetics, with application to quinidine.
- The impact of outlying subjects on decision of bioequivalence.
- The impact of patient compliance on drug concentration profile in multiple doses.
- Thrombin: science and application in clinical practice.
- Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody.
-
Keywords of People
- Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
- Barker, Piers Christopher Andrew, Professor of Pediatrics, Pediatrics, Cardiology
- Cohen-Wolkowiez, Michael, Professor of Pediatrics, Pediatrics, Infectious Diseases